On 30 September, master’s students of the educational programme «Industrial and Pharmaceutical Biotechnology» took part in a guest lecture and discussion held within the course «Quality Management Systems in Manufacturing», featuring Rymma Battalova, the qualified person responsible for pharmacovigilance at the pharmaceutical company «Arterium». Ms Rymma has repeatedly accepted the invitation of the course lecturer Svitlana Starovoitova, and this academic year was no exception.
The lecture opened with the words of the renowned Swiss physician and alchemist Paracelsus: «Everything is poison, and the dose determines the medicine». It is precisely the qualified person responsible for pharmacovigilance at an enterprise who is responsible for the safety of medicinal products. The safety of a medicinal product is determined by the ratio of such indicators as benefit/risk, but this ratio is never constant. The master’s students learned about all of this and much more during a lively discussion with Rymma Battalova.
Here are direct comments from the first-year master’s students:
Anastasiia Hirina (PFB-1-1M): «Today we had a unique opportunity to attend a lecture by Rymma Battalova – the qualified person responsible for pharmacovigilance at JSC «Kyivmedpreparat» (TM «Arterium»).
The lecture addressed many issues that are highly relevant today, such as: pharmacovigilance and its importance, the quality of medicinal products and the criteria by which it is determined; the «thalidomide disaster» was mentioned, along with its cause and the terrible consequences that affected the lives of thousands of people, and especially children. Reference was made to the conclusions and innovations that emerged in the field after this disaster, and once again the importance of conducting appropriate studies before placing any medicinal product on the market and of following the instructions was emphasised. The topic of generics and the state of the modern pharmaceutical industry in Ukraine was also not left aside.
The lecture was extremely interesting and useful, especially because it was held in a discussion format and students could take direct part in discussing the questions raised. It was also valuable because the lecture examined many practical situations and issues that can be relevant even in everyday life. For example, we learned that Analgin is in fact not as bad a medicine as some imagine it to be due to a lack of information. It has excellent antipyretic properties and is especially effective at very high temperatures in children. At the same time, it should be used only in emergency cases because of its side effects.
Overall, attending such a lecture by a specialist in this field was a very interesting experience, and we are grateful for this opportunity!»
Petro Holchyk (PFB-1-1M): «Rymma Battalova’s lecture on pharmacovigilance, judging by her professional reputation, was very informative and in-depth. Ms Rymma has considerable experience in this field, which enables her to cover complex topics such as monitoring the safety of medicinal products, preventing side effects, and the importance of careful monitoring of medicines on the market.
Pharmacovigilance is a critically important part of medicine that helps ensure patient safety. In her lecture, she focused on international standards, the role of regulatory authorities, and the importance of feedback from doctors and patients.
The lecture included practical cases and real-life examples that were interesting.
We discussed the difference between the applicant and the manufacturer, as well as the new adoption of the eCTD format, which is used in Europe, where everything is carried out electronically.
Ms Rymma communicated with us, the audience, as colleagues throughout, and this greatly impressed us.
I would like to thank Rymma Battalova and the pharmaceutical company “Kyivmedpreparat” for the informative lecture, as well as the University for organising it».
Volodymyr Verbiian (PFB-1-1M): «Everything is medicine, everything is poison; it is only a matter of the dose. This statement, voiced by Paracelsus centuries ago, is still fundamental to pharmacy and medicine. Any medicinal product has certain side effects and is capable of causing harm rather than benefit if dosed incorrectly. Even water for injection can have a side effect – it was with this very premise that Rymma Battalova began her open lecture on the pharmacovigilance system. When carrying out pharmacovigilance, one must not reject medicines simply because they have a side effect; it is necessary to assess to what extent the positive therapeutic effect outweighs the negative side effects, to calculate the dosage so as to minimise the side effect, to warn of the risks in the instructions, and to take them into account when prescribing to a particular patient».
Kateryna Hvozdetska (PFB-1-1M): «On 30 September, within the course «Quality Management Systems in Manufacturing», first-year master’s students had a unique opportunity to gain professional knowledge from Rymma Battalova – the qualified person responsible for pharmacovigilance at JSC «Kyivmedpreparat» (TM «Arterium»).
Pharmacovigilance is a quality system for medicinal products (MPs) that consists of the detection, collection, assessment, study, and prevention of adverse reactions. In other words, it is, so to speak, a genuine guarantee for the patient regarding the quality, efficacy, and safety of medicinal products. Therefore, the lecture was primarily devoted to the importance of maintaining the pharmacovigilance system!
During the meeting, we discussed an enormous tragedy of humankind – the thalidomide disaster, after which medicinal products began to be monitored: in the 1950s, the drug thalidomide was used in pregnant women to relieve nervousness, convulsions, and early toxicosis. Pregnant women felt better, the dose and effect seemed to be harmonised, and nothing hinted at trouble. However, most regrettably, more than 10,000 children were born in Western Europe with congenital malformations, namely with impaired development of the upper and lower limbs, or their complete absence altogether. That is, as it turned out, the drug had a fetotoxic effect. Thus, the thalidomide tragedy was the turning point showing that a medicinal product must be monitored – not only observing the positive effect after administration, but also how it behaves over a prolonged period!
Later, during laboratory studies of thalidomide, it was established that this drug is effective in combination therapy for the treatment of myeloma skin disease. Accordingly, for cancer patients, the thalidomide molecule is capable of saving lives!
Thus, it can be concluded that pharmacovigilance is patient-oriented, and the product manufactured at an enterprise must be as beneficial as possible. The «benefit/risk» ratio is a dynamic concept. It is important to remember that the expected benefit of using a medicinal product must outweigh the potential risks, and the risks, in turn, must be minimal, acceptable, and manageable.
We are extremely grateful to Rymma Battalova for sharing valuable information and her own experience in the field of pharmacovigilance with us, which will undoubtedly help us in our future professional careers!»
Anastasiia Onyshchenko (PFB-1-1M): «On 30 September, within the course «Quality Management Systems in Manufacturing», we had a wonderful opportunity to talk with Rymma Battalova – the qualified person responsible for pharmacovigilance at JSC «Kyivmedpreparat» (TM «Arterium»), who shared valuable experience and knowledge in this field.
Our meeting began with a detailed discussion of the three main principles, the so-called «three pillars», on which the entire pharmacovigilance system is based: quality, efficacy, and safety. These are fundamental aspects that are integral components of any process involving medicinal products.
• quality ensures compliance with manufacturing standards and control over every stage of drug development;
• efficacy guarantees that the medicine genuinely performs its therapeutic function and brings benefit to the patient;
• safety is aimed at reducing and identifying possible risks to health, ensuring that the benefit of using the drug significantly outweighs the potential dangers;
All these components are interconnected and form a reliable system aimed at protecting patients and increasing trust in medicinal products.
We also examined the main aspects of monitoring the side effects of medicinal products, the current requirements for pharmacovigilance systems, and emphasised the importance of continuous improvement of processes at pharmaceutical enterprises.
We sincerely thank Rymma Battalova for her time, professionalism, and the valuable knowledge she shared with us!»
We sincerely thank the specialists of «Arterium» for their ongoing support, fruitful cooperation, and invaluable contribution to the professional development of our master’s students. Your professionalism and willingness to share knowledge are invaluable in shaping a new generation of highly qualified specialists!










